BioStock: CombiGene on the first in vivo study in the lipodystrophy project CGT2

Nov 19, 2020

CombiGene’s lipodystrophy project CGT2 is developing according to plan and has recently started the first in vivo studies. Read the interview in BioStock where CombiGene’s CEO Jan Nilsson talks about this exciting project in more detail.
The interview >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Medicon Village, SE-223-81 Lund


Linked In     Twitter      Facebook